Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review
Neurological Sciences · 2025-05 · 46 (5) · 1995-2005
DOI: 10.1007/s10072-024-07843-8 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neurological Sciences, online erschienen am 17.01.2025. Verfasst von Jiaming Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Autoantibodies, Receptors, N-Methyl-D-Aspartate, Encephalitis, Hashimoto Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Fc receptor (FcRn) inhibitors can ameliorate autoimmune conditions such as myasthenia gravis through a rapid and specific clearance of serum IgG levels, and they also have potential for future use in a wider variety of antibody-mediated autoimmune diseases. Some patients with therapy-refractory autoimmune encephalitis (AE) continue to be unresponsive to initial and secondary treatment regimens. A 32-year-old male presented with predominant psychiatric symptoms and seizures, along with imaging evidence indicating multifocal cerebral cortical involvement. Neural antibody testing revealed dual positivity for N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated 1 (LGI1) antibodies in both serum and cerebrospinal fluid (CSF). Human leukocyte antigen (HLA) genotyping revealed the presence of the DQB1*03:01 and DQB1*06:01 alleles in the patient. Treatment with efgartigimod, the FcRn inhibitor, led to significant clinical improvements accompanied by a significant decrease in both anti-NMDAR and anti-LGI1 antibody levels. Herein, we report a rare case of therapy-refractory anti-NMDAR AE coexisting with positive LGI1 antibodies. Efgartigimod demonstrates promising potential for treating antibody-mediated AE. Clinical trial number Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Xinhua Hospital of Hubei University of Chinese and Western Medicine, Wuhan, China.
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. liuzhijunhubei@163.com.
- Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. wuyan_union@hust.edu.cn.
Zitieren
APA
Xu, J., Guo, Z., Zhao, J., Chen, Y., Liu, Z., & Wu, Y. (2025). Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review. Neurological Sciences, 46(5), 1995-2005. https://doi.org/10.1007/s10072-024-07843-8
Vancouver
Xu J, Guo Z, Zhao J, Chen Y, Liu Z, Wu Y. Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review. Neurological Sciences. 2025;46(5):1995-2005. doi:10.1007/s10072-024-07843-8
BibTeX
@article{Xu2025,
author = {Xu, Jiaming and Guo, Zhenli and Zhao, Jie and Chen, Yun and Liu, Zhijun and Wu, Yan},
title = {Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review},
journal = {Neurological Sciences},
year = {2025},
volume = {46},
number = {5},
pages = {1995--2005},
doi = {10.1007/s10072-024-07843-8}
}
EUVIMED